PredictImmune Collects €11 Million in Series B Funding

PredictImmune’s products have landed them €11 million in funding in their Series B round. Their blood tests allow physicians to identify whether an immuno-deficiency disease is likely to be chronic. Physicians can then provide the treatments more effective at earlier stages of the disease. The Cambridge-based company plans to use the investment to improve their technology and expand throughout Europe. The funding brings the company’s total capital to €20.8 million.

Revolutionary Diagnostic Technology 

Physicians, patients and investors are all interested in the technology for its ability to better identify treatments for immuno-deficiency diseases. PredictSURE IBD™, the blood tests method they developed, can indicate the course of an instance of irritable bowel syndrome at the time of diagnosis. Knowing early the severity of a disease allows physicians to implement treatments that are most effective in the disease’s onset. This saves time and potential suffering through the process of trial and error with treatments. 

“PredictImmune is at the forefront of personalized medicine, enabling improved treatment choice for patients with immune-mediated diseases,” said Michael Anstey, Partner at Cambridge Innovation Capital. “We are especially excited about their lead product PredictSURE IBD™, which has the potential to end ‘trial-and-error medicine’ for patients suffering with IBD.”

To Expanding and Perfecting the Pipeline

The funding will support product rollout across Europe, US, UK and the rest of the world. Additionally, PredictImmune plans to develop new tests that identify the most effective treatments for other auto-immune diseases such as lupus. Overall, the company aims to enrich and complement their product portfolio in the coming years. 

“I am delighted with the level of investment secured in this latest round. It’s particularly gratifying to see our existing investors’ confidence in PredictImmune as they follow their initial investments and equally exciting to welcome new investors too. This investment will enable us to keep up the momentum, pushing on with our commercial expansion across the UK, Europe, the USA and rest of the world, whilst also allowing for the expansion and development of our product pipeline,” said CEO Paul Kinnon.


More from author

Want to stay up to date with the latest news?

We would love to hear from you! Please fill in your details and we will stay in touch. It's that simple!